GlassScriptPhysician profile
Jasna Kojic
NPI 1568427193
$2,734.15
in general payments reported to CMS, 2019-2025
15 companies · $53.49 in 2025
The $53.49 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,010 · 2020: $181 · 2021: $79.62 · 2022: $73.22 · 2023: $169 · 2024: $167 · 2025: $53.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $989.92 | 2019-2020 | |
| Eisai INC. | $455.73 | 2019-2020 | |
| Ucb, INC. | $273.25 | 2019-2024 | Briviact |
| Greenwich Biosciences, INC. | $230.40 | 2019 | |
| Tris Pharma INC | $125.93 | 2019-2024 | Dyanavel Xr |
| Neos Therapeutics, LP | $119.43 | 2019-2023 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $101.68 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $94.46 | 2022-2025 | |
| Neurelis, INC. | $88.13 | 2020-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $72.92 | 2023-2024 | Daybue |
| Supernus Pharmaceuticals, INC. | $60.82 | 2021-2023 | Qelbree |
| Novartis Pharmaceuticals Corporation | $42.00 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $28.42 | 2023 | Fycompa |
| Biomarin Pharmaceutical INC. | $26.13 | 2019 | |
| Azurity Pharmaceuticals, INC. | $24.93 | 2024 | Zonisade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasna Kojic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.